SCYNEXIS to Provide a Corporate Update and Report Third Quarter 2021 Financial Results on November 10

Rhea-AI Summary

SCYNEXIS, Inc. (NASDAQ: SCYX) has announced a conference call scheduled for November 10, 2021, at 8:30 a.m. ET to discuss its third-quarter financial results for the period ending September 30, 2021. The call will provide a corporate update on the company's pioneering efforts in developing innovative antifungal medicines, including the recently launched BREXAFEMME (ibrexafungerp), which was FDA-approved on June 1, 2021. Investors can access the live call via phone or webcast, with a replay available on the SCYNEXIS website for 90 days.

Positive

• Launch of BREXAFEMME (ibrexafungerp) as FDA-approved antifungal product.
• Ongoing development for the prevention of recurrent vulvovaginal candidiasis and treatment of invasive fungal infections.

Negative

• None.

JERSEY CITY, N.J., Nov. 03, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 10, 2021, to provide a corporate update and discuss the Company’s financial results for the third quarter ended September 30, 2021.

Conference call and webcast details:

Investors (domestic): (877) 705-6003
Investors (international): (201) 493-6725
Conference ID: 13724235
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1504710&tp_key=3a6a6b5742

A live audio webcast can be accessed by visiting the Investor Relations section of the Company’s website, www.scynexis.com. A replay of the webcast will be archived on the SCYNEXIS website for 90 days following the event.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS scientists are developing the company’s lead asset, ibrexafungerp (formerly known as SCY-078), as a broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings. SCYNEXIS has initiated the launch of its first commercial product in the U.S., BREXAFEMME^® (ibrexafungerp tablets), which was approved by the U.S. Food and Drug Administration (FDA) on June 1, 2021. In addition, late-stage clinical development of ibrexafungerp for the prevention of recurrent vulvovaginal candidiasis (rVVC) and the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. For more information, visit www.scynexis.com. 

CONTACT: 

Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com

Media Relations
Gloria Gasaatura
LifeSci Communications
Tel: (646) 970-4688
ggasaatura@lifescicomms.com

FAQ

What are the details of SCYNEXIS's Q3 2021 financial results conference call?

SCYNEXIS will host a conference call on November 10, 2021, at 8:30 a.m. ET to discuss its financial results for the third quarter ended September 30, 2021.

What is BREXAFEMME and when was it approved?

BREXAFEMME (ibrexafungerp) is an antifungal product approved by the FDA on June 1, 2021, developed by SCYNEXIS.

How can I access the SCYNEXIS conference call?

Investors can access the call by dialing (877) 705-6003 for domestic calls or (201) 493-6725 for international calls, using Conference ID: 13724235.

Where can I find the replay of the SCYNEXIS conference call?

The replay of the conference call will be available on the SCYNEXIS website for 90 days following the event.